CARLSBAD, Calif., Jan. 29,
2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, announced
today the appointment of Adele Gulfo to its Board of
Directors. Ms. Gulfo brings nearly three decades of executive
leadership experience to the TYRA board, with a strong track record
in developing and commercializing some of the world's best-selling
medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma.
"Adele is one of the most accomplished drug developers in our
industry, with nearly thirty years of global expertise in product
commercialization. She has been instrumental in the development and
approval of multiple drugs across several therapeutic areas,
including blockbuster medicines like LIPITOR® and
CRESTOR®," said Todd
Harris, CEO of TYRA. "Adele has a diversified background
both as a pharmaceutical executive and board member, with a wealth
of knowledge in growing oncology business units. Her experience in
launching ORGOVYX® for prostate cancer will be
particularly valuable as we plan for late-stage development of
TYRA-300 in non-muscle invasive bladder cancer. We look forward to
Adele's insights as we advance our precision medicine pipeline and
continue to grow TYRA."
Most recently, Ms. Gulfo served as Chief Executive Officer,
Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where
she led the commercial and development portfolio for multiple
therapeutic areas including oncology, rare disease, urology, CNS
and Women's Health. Previously, Ms. Gulfo served as chief
commercial and business development officer at Sumitovant Biopharma
from 2020 to 2023. Previously, she served as chief commercial
development officer at Roivant Sciences, where she was influential
in the formation of Sumitovant and in preparations for the launches
of key brands, including ORGOVYX® (prostate cancer),
GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and
MYFEMBREE (women's health). Adele was the president and general
manager of Pfizer's $12B+ U.S. primary care business unit, as well
as country manager for Pfizer's U.S. Biopharma business, including
specialty and oncology business units. Earlier in her career at
Pfizer, Adele was instrumental in the development, launch, and
commercial success of LIPITOR®, which became the
world's best-selling medicine. Prior to Pfizer, Adele held vice
president roles within AstraZeneca, including business development
and innovation and commercial readiness, as well as the
multi-billion-dollar cardiovascular business unit. She oversaw the
launch of Crestor® and its growth into a $2 billion medicine.
Ms. Gulfo received a BS in biology from Seton Hall University and an MBA in marketing with
highest honors from Fairleigh Dickinson
University. She studied post-graduate molecular biology at
the University of Medicine and Dentistry of
New Jersey where she began her career. Ms. Gulfo has
been awarded several patents over her career and has extensive
public company board experience. Currently, Ms. Gulfo serves
on the board of directors of Enpro, a publicly traded industrial
engineering firm, and the Innovation Growth Board for Mass General
Brigham, the largest hospital-based research enterprise in
the United States.
"TYRA has great potential to develop best-in-class precision
medicines in therapeutic areas like non-muscle invasive bladder
cancer and skeletal dysplasia, which represent large market
opportunities where innovation is desperately needed," said Ms.
Gulfo. "I look forward to partnering with the executive leadership
team and other members of the board and leveraging my experience to
advance and grow TYRA's pipeline."
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's expertise
in FGFR biology has created a differentiated pipeline with three
clinical-stage programs in targeted oncology and genetically
defined conditions. The Company's lead precision medicine stemming
from SNÅP, TYRA-300, is a potential first-in-class selective
FGFR3 inhibitor that is designed to avoid the toxicities associated
with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for
the FGFR3 gatekeeper mutations. TYRA-300 is expected to be
evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301
for pediatric achondroplasia and SURF301 for metastatic urothelial
cancer. TYRA is also developing TYRA-200, an oral, investigational,
FGFR1/2/3 inhibitor, in the SURF201 study for metastatic
intrahepatic cholangiocarcinoma, and TYRA-430, an oral,
investigational FGFR4/3-biased inhibitor for
FGF19+/FGFR4-driven cancers. TYRA is based
in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us
on LinkedIn.
Forward-Looking Statements
TYRA cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to: the expected advancement of our pipeline and our
growth; the potential to develop next-generation precision
medicines and their potential to be first-in-class and/or
best-in-class; the potential safety and therapeutic benefits of,
and market opportunities for, our product candidates; the expected
timing and phase of development of TYRA-300; and the potential
for SNÅP to develop therapies. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: later developments with the FDA may be inconsistent
with prior feedback from the FDA; we are early in our development
efforts, have only recently begun testing TYRA-300 and TYRA-200 for
oncology in clinical trials and the approach we are taking to
discover and develop drugs based on our SNÅP platform is novel and
unproven and it may never lead to product candidates that are
successful in clinical development or approved products of
commercial value; potential delays in the commencement, enrollment,
data readouts and completion of preclinical studies and clinical
trials; results from preclinical studies or early clinical trials
not necessarily being predictive of future results; interim results
of a clinical trial are not necessarily indicative of final results
and one or more of the clinical outcomes may materially change as
patient enrollment continues, following more comprehensive reviews
of the data, as follow-up on the outcome of any particular patient
continues and as more patient data becomes available, including the
risk that unconfirmed responses may not ultimately result in
confirmed responses to treatment after follow-up evaluations;
unexpected adverse side effects or inadequate efficacy of our
product candidates that may limit their development, regulatory
approval, and/or commercialization; the potential for our programs
and prospects to be negatively impacted by developments relating to
our competitors, including the results of studies or regulatory
determinations relating to our competitors; and other risks
described in our prior filings with the Securities and
Exchange Commission (SEC), including under the heading "Risk
Factors" in our annual report on Form 10-K and any subsequent
filings with the SEC. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and we undertake no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-appointment-of-adele-gulfo-to-board-of-directors-302363721.html
SOURCE Tyra Biosciences
